miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 4, 2026

Analysts Say ‘Load Up’ on These 2 Nuclear Power Stocks — Here’s Why

View original at finance.yahoo.com
Analysts Say ‘Load Up’ on These 2 Nuclear Power Stocks — Here’s Why The widespread push toward energy sector decarbonization is well underway, and usually turns investor attention toward wind or solar power…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • CEG remains best Independent Power Producer idea with ideal mix and scale of assets, leadership position on nuclear contracting, with FERC/PJM regulatory clarity creating opportunities

    80% confidence
  • Overweight rating on Constellation Energy with $460 price target

    80% confidence
  • Outperform rating on Terrestrial Energy with $15 price target

    80% confidence
  • Terrestrial is attractively valued relative to its nuclear reactor technology peer group, with market cap ~37% below peer median despite strong regulatory progress and commercial engagement

    80% confidence
  • Terrestrial maintains sizable cash balance representing ~27% of market cap vs peer median of 14%, providing meaningful liquidity runway to advance licensing, engineering and business development

    80% confidence
  • Every week there are announcements of new companies or governments expanding nuclear capacity or revisiting prior stances on nuclear as the world seeks ways to expand, accelerate or incentivize new nuclear capacity

    80% confidence
  • Near-term catalysts include hyperscaler deal by year-end, Calpine accretion, costs coming down on Crane restart, and uprate opportunities moving above 2 GW fleetwide

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Analysts Say ‘Load Up’ on These 2 Nuclear Power Stocks — Here’s Why — Source | Via News | es.VIA.NEWS